Ortec finishes successful trial of wound sealant

The Hadasit Bio portfolio company believes it will obtain FDA approval by year end and begin marketing its OrCel product in 2007.

Hadasit Bio Holdings Ltd. (TASE:HDST), yesterday announced that its portfolio company Ortec International Inc. (OTCI.OB) has successfully completed trials of its OrCel wound sealant. Ortec said, OrCel healed more wounds and achieved 100% wound closure of those wounds sooner in comparison to the control group.” The company will submit the trial results to the US Food and Drug Administration (FDA) and hopes to receive a reply by year end.

Hadasit Bio merged a portfolio company Hapto Biotech Inc. with Ortec. Hadasit Bio now owns 8% of Ortec, which had a market cap of $6.9 million before the announcement. Hadasit Bio is a subsidiary of Hadassah Medical Organization’s technology transfer company Hadasit Medical Research Services and Development Ltd.

The FDA has already approved one of Ortec’s wound closing products, and the company is now building a marketing network for the product’s launch in the US. The product closes difficult wounds, such as skin ulcers in limbs or from diabetes, using a collagen matrix with embedded cells that form skin cells. The material is kept chilled, in contrast to OrCel, which is frozen and therefore easier and cheaper to transport.

Ortec plans to launch its chilled wound treatment in early 2007. This product has one large competitor in the market; OrCel has no competitor at this time. Both products target a huge potential market that currently lacks good treatments.

Hapto Biotech’s dowry for its merger with Ortec is a next-generation wound closing product that does not require spreading collagen onto cells to induce them to change into skin cells, but haptides (active peptides), which can attract skin cells from surrounding tissue into the collagen matrix. Hapto Biotech is also developing fibrin microbeads (the basic compound in blood clots) on which the skin cell attracting haptides are spread. These two products are designed to reduce wrinkles, and mainly target the cosmetic market.

Published by Globes [online], Israel business news - www.globes.co.il - on September 14, 2006

© Copyright of Globes Publisher Itonut (1983) Ltd. 2006

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Joseph Papa Perrigo up for sale

The pharmaceutical firm is seeking a merger at a premium on its $20 billion market cap.

Twitter Facebook Linkedin RSS Newsletters גלובס